HALIFAX, Jan. 23 /CNW/ - ImmunoVaccine Technologies Inc. (IVT) announced
today that it has met with Health Canada's regulatory affairs division, the
Biologics and Genetic Therapies Directorate, to discuss requirements for a
Phase I clinical trial application. For Phase I human clinical trials, IVT
plans to combine novel antigens with its vaccine-enhancement technology, the
"We are seeing impressive pre-clinical results with the VacciMax(R)
platform," said Dr. Randal Chase, president and CEO of IVT. "The comments from
the Biologics and Genetic Therapies Directorate are much appreciated because
they give us direction as we proceed with our clinical development in Canada,"
said Dr. Chase.
IVT will be in Phase I clinical trial in the US as a result of its
acquisition of Immunotope, a Pennsylvania-based company. The Phase I trial is
evaluating the safety of candidate antigens for a therapeutic vaccine in
ovarian and breast cancer patients.
ImmunoVaccine Technologies Inc. is a private, clinical-stage, vaccine
development company. Through its own biotech research and collaborations with
partners, IVT creates vaccines with the potential to help save and improve
lives around the world.
The company, using its proprietary VacciMax(R) platform, is able to
stimulate an earlier, more powerful, long lasting immune response that could
provide a new way to treat cancer and infectious diseases.
In December 2007, IVT signed a binding MOU to acquire Pennsylvania-based
Immunotope Inc. The acquisition enables IVT to create an entire pipeline of
proprietary therapeutic cancer and infectious-disease specific vaccines. In
January 2008, IVT licensed its technology to Pfizer Animal health, marking a
pivotal step in achieving its vision of delivering breakthrough vaccines.
For further information:
For further information: Brian Lowe, Vice President IVT, (902) 492-1819,
email@example.com; Jennifer Ayotte, Communications, (902) 423-6610 x